Dec 02, 2020 / 09:00AM GMT
Ãystein Soug -
And welcome to this ad hoc webcast and presentation. My name is Ãystein Soug, and I am the CEO of Targovax. So most of you who listen in now will know that we sent out the press release last night on the melanoma, so that is our trial with ONCOS-102 in combination with KEYTRUDA in checkpoint inhibitor refractory melanoma.
And just to be clear upfront, we are very proud about this data. We're very happy, and we think it is very impressive. And to explain why to you and show you the data, we also have Magnus Jäderberg with us today on Video Link from London. Hi, Magnus.
Magnus Jäderberg -
Hello. Good morning.
Ãystein Soug -
If you have questions, you can submit them during the presentation, and we will answer them towards the end. But before we get to Magnus and the data, I will give a few words of introduction and background.
So moving on to Page 4. As you know, we don't develop checkpoint inhibitors in Targovax. But checkpoint inhibitors are what we
Targovax ASA - Special Call Transcript
Dec 02, 2020
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers